Drug Companies Claim Safety of GLP-1 Drugs Amid Controversy

Recent discussions surrounding the safety of GLP-1 weight-loss medications have intensified as drug executives assert that only their products are safe for treating obesity and diabetes. This comes amid a year-long effort to prevent independent laboratories from producing more affordable versions. Former Novo Nordisk CEO Lars Jorgensen testified before Congress last year, claiming that independently compounded GLP-1 drugs have resulted in the hospitalization of over 100 patients and the deaths of 10. These figures were derived from the FDA’s Adverse Event Reporting System (FAERS), but critics argue that this data is flawed.

Advocates for independent pharmacy labs challenge Jorgensen’s assertions. Scott Bruner, CEO of the Alliance for Pharmacy Compounding, emphasized that the FDA warns against drawing definitive conclusions from FAERS data. The agency states that this self-reporting system can include duplicate and incomplete reports, lacks verification, and should not imply a direct cause-and-effect relationship between the drugs and reported health issues.

In the UK, similar data from the Medicines and Healthcare Products Regulatory Agency (MHRA) reported a link between drugs and 82 deaths, without distinguishing between legal and illegal compounded drugs. Of these, 22 deaths were associated with GLP-1 agonists used for weight loss, while 60 were linked to their use for treating type 2 diabetes. Alison Cave, MHRA chief safety officer, stated, “The decision to start, continue, or stop treatments should be made jointly by patients and their doctor, based on full consideration of benefits and risks.”

While mortality from diseases such as flu and COVID-19 is well-documented, there is no verified reporting on deaths of Americans attributed to GLP-1 drugs. Dr. Rozalina McCoy, an endocrinologist and researcher at the University of Maryland School of Medicine, acknowledged the gaps in pharmacovigilance. She underscored the necessity for improved reporting systems to monitor the safety of all medications.

The FDA first approved GLP-1 drugs, also known as glucagon-like peptide-1 receptor agonists, in 2005 for diabetes treatment. Their approval for weight loss in 2014 led to a national shortage expected to last until 2025. Approximately 12% of the adult population in the United States, or around 32 million people, are currently prescribed some form of GLP-1. During shortages or when patients require specific formulations, compounding pharmacies often provide custom prescriptions.

Research published in the Cureus Journal of Medical Science analyzed FAERS data and highlighted a concerning trend. The study identified a significant number of deaths associated with early GLP-1 drugs, such as Byetta and Victoza, with 1,571 and 1,016 related deaths respectively. Additionally, higher rates of adverse reactions were noted with newer semaglutide products, including Ozempic, Rybelsus, and Wegovy.

The FDA has issued updates recommending that physicians monitor patients for depression or suicidal thoughts as a precaution, although a preliminary evaluation found no evidence linking these medications to such thoughts or actions. A report in Nature indicated that previously reported warnings about pancreatitis-related deaths could not be definitively connected to GLP-1 usage.

Contrastingly, a study from University of California, San Diego provided evidence that colon cancer patients using GLP-1 drugs had a significantly reduced mortality rate—15.5% for those on the drugs compared to 37.1% for those not taking them.

Despite the FDA declaring an end to the GLP-1 shortage, access remains a critical issue. Many patients face financial barriers, as insurance coverage for weight-loss medications is limited. Dr. McCoy noted that affordability is now a significant impediment, stating, “Many insurance companies are not covering these drugs for weight loss.” Novo Nordisk currently offers its medications at a cost of $150 per month for those without insurance coverage.

As the debate over GLP-1 drug safety continues, the need for accurate data and effective regulation remains paramount. The outcome of ongoing discussions may significantly impact patient access to these medications and the future of obesity treatment strategies.